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Abstract
To date, no systematic analyses are available assessing concordance of molecular
classifications between primary tumors (PT) and matched liver metastases (LM) of
metastatic colorectal cancer (mCRC). We investigated concordance between PT and
Abbreviations: BRAFm-like, BRAF mutant like; BRAF, v-RAF murine sarcoma viral oncogene homolog B; BRAFwt-like, BRAF wild type like; CMS, consensus molecular subtype; CMS1, consensus
molecular subtype 1; CMS2, consensus molecular subtype 2; CMS3, consensus molecular subtype 3; CMS4, consensus molecular subtype 4; CRC, colorectal cancer; EB, Ethical Board; EMT,
epithelial to mesenchymal transition; FFPE, formalin-fixed paraffin-embedded; HR, hazard ratio; ICF, informed consent form; ICO-IDIBELL, Catalan Institute of Oncology - Bellvitge Biomedical
Research Institute; INT, Instituto Nazionale dei Tumori; IOV, Instituto Oncologico Veneto; KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog; KW-test, Kruskal-Wallis test; LM, liver
metastasis; mCRC, metastatic colorectal cancer; mOS, median overall survival; MoTriColor, Molecularly guided trials strategies in patients with advanced newly molecular defined subtypes of
colorectal cancer; MSI, microsatellite instable; MW-test, Mann-Whitney; OS, overall survival; PT, primary tumor; QC, quality control; SpCorr, Spearman's rank-order correlation; TGFB,
transforming growth factor-beta 1; TGFBa-like, transforming growth factor-beta 1 activating-like; TGFBi-like, transforming growth factor-beta 1 inactivating-like.
Andreas Schlicker, Architha Ellappalayam, and Ines J. Beumer contributed equally to first authorship.
René Bernards and Loredana Vecchione contributed equally to senior authorship.
Received: 23 November 2019 Revised: 4 March 2020 Accepted: 16 March 2020
DOI: 10.1002/ijc.33003
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
Int. J. Cancer. 2020;147:2303–2315. wileyonlinelibrary.com/journal/ijc 2303
Loredana Vecchione, Department of
Hematology, Oncology and Tumor
Immunology (CCM) , Charité Comprehensive
Cancer Center, Charité Universitaetsmedizin
Berlin, Charitéplatz 1/Hufelandweg 9, Ebene
4, Haus 2622,




INTRACOLOR grant funded under the
programme ERA-NET on TRANSCAN 2
LM for four clinically relevant CRC gene signatures. Twenty-seven fresh and 55 for-
malin-fixed paraffin-embedded pairs of PT and synchronous LM of untreated mCRC
patients were retrospectively collected and classified according to the MSI-like,
BRAF-like, TGFB activated-like and the Consensus Molecular Subtypes (CMS) classi-
fication. We investigated classification concordance between PT and LM and associa-
tion of TGFBa-like and CMS classification with overall survival. Fifty-one successfully
profiled matched pairs were used for analyses. PT and matched LM were highly con-
cordant in terms of BRAF-like and MSI-like signatures, (90.2% and 98% concordance,
respectively). In contrast, 40% to 70% of PT that were classified as mesenchymal-like,
based on the CMS and the TGFBa-like signature, respectively, lost this phenotype in
their matched LM (60.8% and 76.5% concordance, respectively). This molecular
switch was independent of the microenvironment composition. In addition, the signif-
icant change in subtypes was observed also by using methods developed to detect
cancer cell-intrinsic subtypes. More importantly, the molecular switch did not influ-
ence the survival. PT classified as mesenchymal had worse survival as compared to
nonmesenchymal PT (CMS4 vs CMS2, hazard ratio [HR] = 5.2, 95% CI = 1.5-18.5,
P = .0048; TGFBa-like vs TGFBi-like, HR = 2.5, 95% CI = 1.1-5.6, P = .028). The same
was not true for LM. Our study highlights that the origin of the tissue may have major
consequences for precision medicine in mCRC.
K E YWORD S
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1 | INTRODUCTION
Colorectal cancer (CRC) is one of the most common cancers world-
wide, with an estimated 1.2 million cases and over 600 000 deaths
per year.1 Due to its relatively asymptomatic progression, patients
are frequently diagnosed with metastatic disease, which is associ-
ated with a five-year survival rate of around 10%.2 Since biopsies
and surgical tissue of metastatic lesions are difficult to obtain, treat-
ment choice is mainly driven by the analysis of the archived primary
tumor.
Coding mutations have been reported to be highly concordant
between primary tumors (PT) and matched liver metastasis (LM).3 This
is also the case for epigenetic and microbiome profiles.4-6 In contrast,
copy number profiles are discordant7,8 possibly pointing at larger
genomic differences between PT and LM.
CRC can also be classified into different molecular subtypes
based on gene expression patterns.9-15 The different molecular sub-
types are characterized by the activation of different biological pro-
cesses, such as microsatellite instability (MSI) and immune
infiltration signaling, canonical epithelial signaling activation, meta-
bolic dysregulation and mesenchymal characteristics. Although these
subgroups have different prognosis, their predictive value, especially
regarding the efficacy of targeted agents, remains under investiga-
tion. In this context, the MoTriColor consortium is currently
exploring the efficacy of specific treatment strategies in molecularly
defined CRC subgroups.16 Published and validated transcriptomic
signatures were mainly developed in stage II and stage III disease,
while metastatic CRC (mCRC) was not systematically investigated.
Moreover, most of the data were generated from archival primary
tumors.
What's new?
No systematic analyses have assessed concordance of
molecular classifications between primary tumors and mat-
ched liver metastases in metastatic colorectal cancer
(mCRC). Here, the authors show that 40% to 70% of primary
colon tumors cease to exhibit an epithelial-to-mesenchymal
transition phenotype (EMT) at the transcription level in their
matched liver metastasis (LM). While EMT-positive PT show
worse outcome compared to EMT-negative PT, this is not
true for LM. The data argue in favor of using the primary
tumor for molecular analysis rather than distant metastases.
Overall, this study highlights that tissue origin may have
major consequences for precision medicine in mCRC.
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Importantly, no systematic studies have investigated the concor-
dance of classification of PT and LM according to different gene
expression signatures. Few studies have reported about similarity in
transcriptomic profiles between PT and matched LM, but they were
inconclusive because of their small size and inclusion of synchronous
and metachronous tumors.17,18 Here, we aimed to systematically
study PT and their matched LM and to assess if gene expression sig-
natures currently investigated in the MoTriColor consortium16 as well
as the Consensus Molecular Subtype (CMS) classification15 are con-
cordant between matched pairs. Recently, Trumpi et al19 reported
that chemotherapy can affect the molecular classification of CRC. In
addition, Isella et al20 showed that the features of the mesenchymal
subtype can be ascribed to its stromal component. Therefore, to avoid
any bias that could be related to systemic treatment and different
metastatic locations, we only included untreated primary CRC and
their matched synchronous LM. Moreover, we investigated if the clas-
sification of some tumors, especially the ones classified as belonging
to mesenchymal subgroups, could be influenced by the tumor micro-
environment. Such data could help to understand if the transcriptomic
molecular profiling of PT is sufficient to inform treatment choice or if
molecular profiling of matching metastases is required to guide clini-
cians for individualized treatment recommendations in mCRC.
2 | MATERIALS AND METHODS
2.1 | Patient samples
We collected retrospectively samples of PT and matching synchro-
nous LM from three different academic institutions: Catalan Institute
of Oncology (ICO)-Bellvitge Biomedical Research Institute (IDIBELL-
Barcelona), Istituto Nazionale dei Tumori (INT-Milan) and Istituto
Oncologico Veneto (IOV-Padua). Samples were collected from
treatment-naive cases with synchronous liver metastases at time of
diagnosis and available clinical-pathological annotations. We restricted
our study to these inclusion criteria to exclude potential effects of
earlier treatments or different metastatic locations.19 Clinico-
pathological annotations included are reported in Table 1.
Based on these eligibility criteria, 82 matched mCRC pairs were col-
lected. Of these, 24 fresh and 38 formalin-fixed paraffin-embedded
(FFPE) tissue pairs were successfully processed and passed quality con-
trol. For 11 patients, we received both fresh and FFPE tissues of mat-
ched pairs from ICO-IDIBELL, which were used to investigate the
influence of tissue preservation technique on gene expression (Figure 1).
Research was performed according to the principles of the Decla-
ration of Helsinki. All patients were under clinical follow-up surveillance
according to the Spanish or Italian National Guidelines. All patient sam-
ples and data were anonymized in accordance with national ethical
guidelines21 and study samples had Institutional Review Board
approvals for the anonymized use of archival tissues. In particular,
the Institutional Review Board of the INT approved the study (study
number 117/15) and all alive patients signed a written informed con-
sent. The Ethical Board (EB) of the IOV approved the study (study
2017/70) and the local EB of ICO-IDIBELL approved the study
(PR030/17; study 2017/70). For ICO-IDIBELL, none of the patients
signed a written informed consent form (ICF) because patients were
dead or lost during the follow-up. The Spanish law allows using tumor
samples collected before 2006 without an ICF if it is not possible to
have it.
2.2 | Microarray processing and quality control
Total RNA was isolated from fresh-frozen and FFPE tissues with at
least 30% of tumor cells. If possible, tissue enrichment was performed
for samples that did not meet these criteria. RNA isolation and microar-
ray processing were performed as described previously.9,10,12,13 For
fresh tissue, RNA was isolated using the RNeasy micro kit (Qiagen,
Hilden, Germany). Quality was assessed using an RNA 6000 Nano total
RNA-Chip (Agilent Technologies, Santa Clara, California). Only samples
with RIN ≥ 6 were included in further analyses. Two hundred nano-
grams of total RNA were reverse transcribed, amplified and labeled
with either Cy3 (sample) or Cy5 (reference sample) using the QuickAmp
Labeling kit (Agilent Technologies), and subsequently purified using the
Qiagen RNeasy mini kit. Cy3-labeled cDNA and Cy5-labeled cDNA
were pooled (equimolar) and hybridized to the microarray.
For FFPE tissues, RNA was isolated using the RNeasy FFPE kit
(Qiagen). Fifty nanograms of total RNA were reversed transcribed and
amplified using the TransPLEX C-WTA whole-transcriptome amplifi-
cation kit (Rubicon, Ann Arbor, Michigan) and labeled with Cy3 using
the Genomic DNA Enzymatic Labeling Kit (Agilent Technologies). For
the microarray processing, cDNA was hybridized to custom full
genome arrays (array design based on Agilent Catalog #G2514F) and
washed according to the Agilent standard hybridization protocol
(Agilent Oligo Microarray Kit, Agilent Technologies). Arrays were
scanned with a dual laser scanner (Agilent Technologies).
Probes that showed nonuniformity of the signal as identified by
the feature extraction software were omitted from further analyses.
Image analysis of the scanned arrays was performed to quantify fluo-
rescent intensities using Feature Extraction software version 9.5 and
11.5.1.1 (Agilent Technologies), for fresh and FFPE tissues, respec-
tively. The feature extraction process included within-array normaliza-
tion, which was performed using the default method for within-array
normalization of Agilent microarrays (Lowess correction method using
a linear polynomial [locally weighted linear least square regression]).
Background correction was not applied. The final data sets contained
expression values for 32.164 unique probes for our entire cohort.
Expression values were calculated as sample/reference ratios using
within-array normalized signals (log10[Cy3/Cy5]) for fresh tissue and
represented the gMeanSignal intensities for FFPE tissue.
2.3 | Data analysis
Analyses and visualization of transcriptome data were performed in
R22 and RStudio. To investigate the contribution of the tissue
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preservation on gene expression levels, 11 unique patients' pairs for
which both fresh and FFPE tissues were provided, underwent further
analyses. In particular, 22 fresh samples (primary and metastasis) and
22 FFPE samples (primary and metastasis) were first median centered
separately to remove probe specific bias and then combined together.
Next, samples were clustered using the 64 genes of the MSI-like signa-
ture, the 277 genes of the TGFBa-like signature and the 266 unique
genes of the CMS classification. For these 11 patients, we finally
included the data from the FFPE tissue pairs, thus giving a total of
51 matched pairs. Hierarchical unsupervised clustering of these 51 mat-
ched pairs was performed on genome-wide transcriptome level. All
clusterings (R version 3.1.3) were performed using the “ward.D2”
method in the hclust function, and visualized using ggplot2 (version
3.0.01), dendextend (version 1.12.0), dplyr (version 0.8.3). Colors of the
dendrogram bars were generated using ColorBrewer (version 2.0).
2.4 | Signature and classification readout
Molecular subtyping was performed on the microarray transcriptome
data of the 51 matched pairs, using five patented signatures for
molecular subtype classification in colon cancer (MSI64-gene signa-
ture for fresh tissues, MSI-like FFPE signature, BRAF58-gene signa-
ture for fresh samples, BRAF mutant-like FFPE signature, ABC
TABLE 1 Patients' characteristics for the successfully profiled matched pairs
ICO INT IOV
P-valuen % n % n %
Age at diagnosis
Median-range 59.3 53.4-73.3 64.4 39.5-78.5 70.0 35.6-76.8 .015
Age at surgery
Median-range 62.6 52.6-75.1 64.4 39.5-78.5 73.7 35.6-76.8 .022
Gender
Female 7 28.0 2 15.4 4 30.8 .615
Male 18 72.0 11 84.6 9 69.2
Tumor location
Right 7 28.0 3 23.1 4 30.8 .055
Left 7 28.0 5 38.5 9 69.2
Rectum 11 44.0 5 38.5 0 0.0
Grade
G1 20 87.0 0 0.0 0 0.0 <.001
G2 0 0.0 6 46.2 10 76.9
G3 3 13.0 7 53.8 3 23.1
Diameter
Median-range 47.5 20-60 40 16-75 35 12-80 .605
MSI status
MSS 2 8.0 12 92.3 9 69.2 <.001
MSI 0 0.0 1 7.7 1 7.7
Missing 23 92.0 0 0.0 3 23.1
BRAF
Wild 0 0.0 10 76.9 12 92.3 <.001
Mutant 0 0.0 1 7.7 1 7.7
Missing 25 100.0 2 15.4 0 0.0
KRAS
Wild 2 8.0 6 46.2 6 46.2 <.001
Mutant 0 0.0 6 46.2 7 53.8
Missing 23 92.0 1 7.7 0 0.0
Note: Twenty-five matched pairs were provided by ICO (Catalan Institute of Oncology, Barcelona, Spain) while 13 matched pairs were provided both by
INT (Istituto Nazionale dei Tumori di Milano, Italy) and IOV (Istituto Oncologico Veneto, Padua, Italy), respectively. The following clinical variables were
considered: age at diagnosis, age at surgery, gender, tumor location (right side colon, left side colon, rectum), tumor grade (G1, G2, G3), tumor diameter,
MSI-status, BRAF status, KRAS status. P values are referring to differences in distribution of clinical variables across the three different centers.
Abbreviation: NA, not applicable.
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classification for fresh samples), one under patenting (TGFB
activating-like signature) and the consensus classification (CMS classi-
fication). Additionally, we applied the CMScaller signatures,23 which
are based on cancer cell-intrinsic gene markers.
2.4.1 | Proprietary signatures
The MSI64-gene signature13 was developed using fresh tissues to iden-
tify patients with a gene expression pattern similar to patients that were
MSI-high by clinical tests, and categorizes tumors as microsatellite stable
(MSS)-like or instable (MSI)-like. The BRAF58-gene signature10,12 was
developed using fresh tissues to identify patients with a gene expression
pattern similar to patients with BRAF V600E mutations, and categorizes
tumors into BRAF wild-type (BRAFwt)-like and BRAF mutant (BRAFm)-
like. Both signatures were also adapted for use in FFPE tissues. The
ABC classification9 was specifically developed for fresh tissues and iden-
tifies tumors as A-type (DNA mismatch repair-deficient epithelial sub-
type), B-type (proliferative epithelial subtype) or C-type (mesenchymal
subtype). The TGFB activated (TGFBa)-like signature was developed
specifically for FFPE tissue. The signature categorizes tumors into TGFB
inactivated (TGFBi)-like and activated (TGFBa)-like, with the TGFBa-like
group resembling the C-type and the TGFBi-like the AB-type of the
ABC classification, respectively. The TGFBa-like signature, even if not
yet published, is under investigation in the frame of the MoTriColor
consortium.16 Classification results were generated using proprietary
software based on MATLAB (MathWorks Inc, Natick, Massachusetts).
2.4.2 | Publicly available classification
Probe sequences were aligned to the human transcriptome using
NCBI-Blast to obtain the latest annotation information for generating
the CMS calls. The CMS classification15 was performed in R (version
3.1.122) and RStudio (version 0.98.994) using the CMS calls specific
for the Agilent-platform. Additionally, the CMScaller signatures23
were performed in R (version 0.99.1) which has as input a matrix with
gene expression data and a CMS template.
2.5 | Stroma percentage and microenvironment
assessment
The stroma percentage of the FFPE tissue slides were visually scored
in a blinded manner. The scoring percentages of the hematoxylin and
eosin (H&E) stained 5 μM thick sections were scanned on an Aperio
ScanScope XT (Leica Biosystems, Wetzler, Germany) and uploaded
to the Aperio eSlide Manager (Leica Biosystems). Pre-existing
healthy tissue, necrotic and mucinous areas were excluded from
the scoring. 1X amplification was used to determine the relative
percentages corresponding to the desmoplastic stroma. The tumor
epithelium areas were determined within the tumor field. Stromal
percentage (surrogate) was defined as 100 minus the tumor
percentage. Moreover, to estimate the composition of the tumor
microenvironment, we utilized the Microenvironment Cell
Populations-counter (MCP-counter) method24 which allows a robust
quantification from transcriptomic data of both immune and stromal
cell populations in heterogeneous tissue.
2.6 | Statistical analysis
Data were analyzed using SPSS 22.0 for Windows (SPSS Inc. Chicago,
Illinois). For all statistical analyses, a two-sided P-value of .05 or less
was considered statistically significant.
Sample population homogeneity and normality of distribution
were tested using, respectively, a Pearson chi-square statistic for cate-
gorical variables and an Independent Samples Kruskal-Wallis
(KW) test for the continuous variables.
The overall concordance of molecular profile between PT and
matched LM was estimated using categorical classifications for all
gene expression signatures. For BRAF-like, MSI-like and ABC/TGFBa-
like signatures, the switch between tumor types was calculated using
generalized estimating equations to fit a repeated measures logistic
regression.
Sankey plots were generated using R (version 3.6.1) and the pack-
age networkD3 (version 0.4).
The relationship between stroma percentage (S%) and tissue type
(PT/LM) or molecular subtypes was investigated using a paired t test
for paired PT and LM. For the molecular subtypes either a Mann-
Whitney (MW)-test (TGFBa-like signature) or Kruskal Wallis (KW)-test
(CMS classifier) was used. Spearman's rank-order correlation (SpCorr)
served to measure the correlation between the S% in PT and the S%
in LM. ΔS% was defined as the difference in S% between matched tis-
sue pairs and calculated as ΔS% = S% of LM − S% of PT. An indepen-
dent t-test was used to investigate the relationship between ΔS% and
a Boolean variable indicating a switch or not in molecular subtype of
the TGFBa-like signature or the CMS classifier.
Survival analyses were performed using R (version 3.6.1)
and the packages survival (version 2.44) and survminer (version
F IGURE 1 Workflow design of the study. A total of 55 fresh samples and 110 FFPE samples were collected, ending in 82 matched pairs. For
11 matched pairs, both fresh and FFPE tissue were collected. Upon RNA quality control and tumor content evaluation, samples that fulfill the
criteria were processed on the array. Only successfully profiled PT with their corresponding matched LM were further analyzed for the different
signatures. Further, clustering of these 11 pairs based on the genes belonging to the MSI-like and TGFBa-like signature as well as the CMS
classification was performed. Because differences observed among those 11 pairs were mainly due to intratumor heterogeneity, the 11 FFPE
matched pairs were retained for further analyses and combined with 13 fresh and 27 FFPE pairs. Therefore 51 matched pairs were finally
molecularly classified based on the MSI-like signature, the BRAF-like signature, the ABC/TGFBa-like signature and the CMS classification
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0.4). The Cox proportional hazards model was used to analyze
the association of molecular subtypes with overall survival
(OS), which was defined as the time from surgery until
death from any cause. Kaplan-Meier curves were used to com-
pare the survival distributions of the molecular subtypes
with OS.
F IGURE 2 Clustering based on genes belonging to the MSI-like signature and transcriptome-wide gene expression. A, Clustering of the
11 matched pairs for which we received both fresh and FFPE tissue based on the genes belonging to the MSI-like signature (number genes = 64).
Red rectangles highlight matched pairs that cluster together. T: primary tumor, FFPE tissue; M: matched liver metastasis, FFPE tissue; B: primary
tumor, fresh tissue; C: matched liver metastasis, fresh tissue; Dendrogram bars: Tissue type: fresh tissue (dark gray), FFPE tissue (light gray);
sample info: each color indicates samples belonging to the same patient. B, Unsupervised clustering based on genome wide transcriptomic profile
of 51 matched pairs (13 fresh pairs and 38 FFPE pairs). Red rectangles highlight matched pairs that cluster together P: primary tumor; M: matched
liver metastasis. Dendrogram bars: tissue type (fresh, FFPE); Tumor type (primary, metastasis); Primary tumor location (right colon, left colon,
rectum); Primary tumor grading (G1, G2, G3); Gender (male, female); MSI-like signature (MSS-like, MSI-like); BRAFm-like signature (BRAFwt-like,
BRAFm-like); ABC/TGFBa-like signature (AB/TGFBi-like, C/TGFBa-like); CMS classification (CMS1, CMS2, CMS3, CMS4)
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3 | RESULTS
3.1 | Study population
To gain insights into the concordance of the transcriptomic profiles of
PT and their matched LM, we collected 82 matched mCRC samples.
As summarized in Figure 1, 48 (= 24 pairs) fresh tissue samples were
processed and all passed quality control (QC). The FFPE tissue cohort
contained 76 samples (= 38 pairs) that were available for molecular
subtyping. When we compared the success rate of sample processing
on the gene expression array, we did not observe statistically signifi-
cant differences between the fresh (94.4%) and the FFPE (87.8%)
cohorts (P = .259).
We next sought to investigate if tissue preservation could have
an influence on the gene expression read-out. To this end, we looked
at the expression of genes belonging to the MSI-signature, the
TGFBa-like signature and the CMS classification in the 11 patients'
pairs for which we received both fresh and FFPE tissues.
Unsupervised clustering of these pairs showed that samples derived
from the same patients were clustering together irrespective of tissue
type (Figures 2A and S1A,B). This effect was most apparent when
considering the MSI-like and TGFBa-like signatures (Figures 2A and
S1A). Therefore, we concluded that gene expression differences
between samples from the same patient were mainly due to
intratumor heterogeneity rather than tissue preservation method, as
previously reported for other solid malignancies.25
3.2 | Primary CRC and matched liver metastasis
differ at gene expression level
We next aimed to investigate if transcriptomic profiles of the PT dif-
fered from those of their matched LM. Considering that the tissue
preservation method did not influence the transcriptomic profiles, we
combined the fresh and FFPE pairs. As reported in Figure 1, the final
cohort of 51 successfully profiled matched pairs derived from 13 fresh
pairs and 38 FFPE pairs, combined together. For patient characteris-
tics, see Table 1. Overall, the distribution of the major clinical-
pathological characteristics was similar between the three centers,
except for tumor grading (P < .001), with samples from ICO being
mainly characterized by well-differentiated tumors.
Furthermore, unsupervised clustering of the transcriptome pro-
files of these 51 matched pairs showed two major clusters without
any obvious correlation with molecular subtyping calls or categorical
clinical-pathological variables. As reported in Figure 2B, we neither
observed a clear separation of PT from LM, since each cluster was
characterized by both tissue types, nor a homogeneous clustering of
the PT and their matching LM. Only 13% of the matched pairs
(7 out of 51) clustered together indicating differences in the overall
gene expression profiles. This exploratory analysis suggested that
primary mCRC differ from their matched LM at the transcriptome-
wide level.
3.3 | The mesenchymal profile of primary tumors
is not always retained in their matched liver metastasis
Next, we aimed at comparing four established molecular gene signa-
tures with potential clinical utility in PT and their matched LM. In par-
ticular, both PT and their matched LM were classified as MSI-like or
MSS-like13 and as BRAF m-like or BRAF wt-like.10-12 Tumors were
also classified as being TGFBa-like or TGFBi-like. For this purpose, we
used the ABC classification9 for the fresh tissue samples and the
TGFBa-like signature for the FFPE tissue samples. It is important to
note that the genes belonging to the C-group of the ABC classification
and the TGFBa-like group are highly overlapping and they both
identify tumors showing an epithelial-mesenchymal transition (EMT)
phenotype. Therefore, we classified tumors as AB/TGFBi-like or
C/TGBa-like to give a uniform nomenclature for fresh and FFPE
samples. Finally, the CMS classification15 was applied both to PT and
their matched LM. A schematic overview of the concordance and
changes of the different molecular subtypes between PT and their
matched LM is reported in Figure 3 as well as in Table S1.
Overall, we observed high concordance for the BRAF-like and
the MSI-like signatures between PT and LM, while lower concor-
dance was observed for the TGFBa-like signature and the CMS clas-
sification. Four PT were classified as BRAF wt-like while their
matched LM were classified as BRAF m-like. One PT was classified
as BRAF m-like while its matched LM was classified as BRAF wt-like
(Figure 3A). The overall concordance in terms of BRAF-like signature
between PT and LM was 90.2%; the number of switches was not
statistically significant (P = .177) (Table S1). Only one matched pair
was not concordant in terms of MSI signature, with the PT classified
as MSI-like and its matched LM as MSS-like (Figure 3A). The overall
concordance of MSI-like signature between PT and LM was 98%;
the number of switches was again not statistically significant
(P = .313; Table S1).
Two pairs switched from AB/TGFBi-like in the PT to C/TGFBa-
like in the LM (Figure 3A). More importantly, 10 out of 14 pairs (71%),
whose PT were classified as C/TGFBa-like, were classified as
AB/TGFBi-like in their matched LM showing an overall concordance
of 76.5% (Table S1). This significant switch (P = .020) was also
observed for the CMS4 classification (Figure 3B). Thirteen out of
32 pairs (40.6%), whose PT were classified as CMS4, were classified
as CMS2 in their corresponding LM. One pair, whose PT was classi-
fied as CMS4, was classified as CMS3 in its matched
LM. Furthermore, one pair switched from CMS1 in the PT to CMS4 in
the LM and one pair switched from CMS3 in the PT to CMS2 in the
LM. Within 16 PT that were classified as CMS2, four pairs switched
to CMS4. These results indicated a 60.8% overall concordance for the
CMS classification between PT and matched LM, with major signifi-
cant switches (P = .050) regarding the mesenchymal subtype. Overall,
the switches observed, both for the C/TGFBa-like signature and the
CMS classification, indicate that the mesenchymal profile of 41% or
71%, depending on the classification used, is not retained in their
matched LM.
2310 SCHLICKER ET AL.
3.4 | The loss of mesenchymal profile between
primary tumors and their matched liver metastases is
independent of the tumor microenvironment
Tumor microenvironment and in particular tumor stroma might play a
role in determining the mesenchymal transcriptional profile of CRC.20
We therefore investigated the composition of the microenvironment
in order to better understand the switches of the mesenchymal profile
observed between PT and their matched LM. To this end, we first
quantified the stromal percentage in our samples. Because of a lack of
further available tissue from the fresh pairs, we only considered the
FFPE matched pairs for this analysis.
Overall, we observed similar population means of stroma percent-
ages in PT and LM (P = .097). Also, no correlation was observed
F IGURE 3 Molecular subtypes switch between PT and matched LM. A, Sankey plots showing the switch between PT and LM, in terms of
MSI-like signature, BRAF-like signature, ABC/TGFBa-like signature. The molecular classification of the PT, with the corresponding number of
pairs classified as such, is reported on the left of the Sankey plot. The molecular classification of the matched LM, with the corresponding number
of pairs classified as such, is reported on the right of the Sankey plot. B, Sankey plots showing the switch between PT and LM in terms of CMS
classification. The molecular classification of the PT, with the corresponding number of pairs classified as such, is reported on the left of the
Sankey plot. The molecular classification of the matched LM, with the corresponding number of pairs classified as such, is reported on the right of
the Sankey plot
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F IGURE 4 Estimate survival curves for the CMS classification. Kaplan-Meier plot of overall survival in months. A, Subjects were divided
based on their primary tumor sample's CMS classification. CMS1 and CMS3 were excluded due to the small number of samples classified as such.
The table below the survival plot contains the numbers of samples remaining in each group (strata) at each time point. B, Subjects were divided
based on their metastatic sample's CMS classification; C, subjects were classified based on the CMS classification change from primary tumor
samples to the matched metastatic sample. A two-sided P-value was not applied to C due to the small sample size of the groups
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between stroma percentages in the matched pairs (rho = −.196,
P = .252). We did not observe an association between stroma per-
centage (S%) and CMS classification (P = .127). However, we observed
a significantly higher S% with the TGFBa-like subtype (P = .04). To
understand if a difference in S% could be associated with a switch
from PT to LM in CMS or TGFB classification, we analyzed if the dif-
ference in stroma percentage between PT and LM calculated as the S
%LM − S%PT (ΔS%) was different between switchers and non-
switchers. We did not observe a significant difference in ΔS%
between nonswitchers and switchers neither for the TGFBa-like sig-
nature (P = .607) nor for the CMS classification (P = .076), indicating
that the difference in S% is not associated with a switch in molecular
subtype classification. To confirm this observation, we further used
MCP-counter in order to robustly quantify the absolute abundance of
both immune and stromal cells using the transcriptomic data of our
51 matched samples. As reported in Figure S2, we did not observe a
systematic difference in microenvironment composition between PT
and LM. More importantly, no pattern was observed among the sam-
ples based on the CMS classification.
In addition, because a dedicated translation of the CMS classifica-
tion to metastatic organs of CRC remains pending and by considering
that gene expression signals might be strongly influenced by the organ
of origin, we used the CMScaller classification to compare tumor clas-
sification between PT and LM. Overall, as reported in Figure S3, we
observed a better distribution of the different subtypes both in the PT
and LM, with more tumors classified as CMS3 and CMS1 as compared
to the CMS classification. Nevertheless, the subtype assignments var-
ied significantly (Fisher test, P = .0033) between primary and
metastasis.
In summary, these results indicate that the switch observed
between PT and LM was not influenced by the stromal component,
both evaluated as stromal percentage and by transcriptomic predic-
tion, and that the classification of PT and matched LM are significantly
different both by using the CMS classification and a classification that
is based on cancer cell-intrinsic gene markers as the CMScaller.
3.5 | The molecular profile of the primary tumor
determines the outcome of mCRC patients
independent from the molecular profile of their
matched liver metastases
Next, we investigated if differences observed in CMS classification
and TGFBa-like signature between PT and LM could affect patient
overall survival (OS). Median OS (mOS) for PT was 165.9 months vs
37.3 months in CMS2 and CMS4, respectively (HR = 5.2, 95%
CI = 1.5-18.5, P = .0048; Figure 4A) and 51.6 vs 24.0 months for
TGFBi-like vs TGFBa-like, respectively (HR = 2.5, 95% CI = 1.1-5.6,
P = .028; Figure S4A). These results confirmed that tumors classified
as positive for a mesenchymal phenotype have a worse prognosis
when compared to tumors classified as nonmesenchymal.14,15 In con-
trast, no mOS differences were observed among LM classified as
CMS2 vs CMS4 (51.6 vs 42.1 months, respectively, HR = 1.5, 95%
CI = 0.7-3.5, P = .28; Figure 4B) and TGFBa-like vs TGFBi-like (59.7 vs
45.4 months, respectively; Figure S4B). Finally, when we compared
matched pairs that switched phenotype with the ones that did not
switch phenotype, we did not observe major differences. Even if
exploratory, these analyses confirmed previous observations,14,15 that
also report mesenchymal-like tumors to have a worse outcome com-
pared to nonmesenchymal tumors. Interestingly, this effect was inde-
pendent of the transcriptomic profile of their matched LM (Figures 4C
and S4C).
4 | DISCUSSION
Currently, the treatment of mCRC is based on the molecular profile of
the archived primary tissue and this is sufficient in most cases to iden-
tify mutations in genes that are predictive of response to conventional
biological agents.3,26 Nevertheless, it has been shown that primary
colon tumors and their matched metastases might differ in terms of
copy number alterations.7,8 This raises the possibility that LM could
have different actionable targets as compared to their matched PT. In
addition, this could imply that the transcriptomic profile of PT and
their matched LM might also differ. Different molecular classifications
for CRC are currently under investigation for their predictive role in
response to specific treatment strategies. It is therefore important to
understand if the transcriptomic profile of archived primary tumor is
sufficiently informative to predict the efficacy of certain treatment or
the gene expression profile of their matched LM is required.
In this retrospective study, we analyzed the concordance of gene
expression signatures with potential treatment implications in 51 mat-
ched samples of primary colon tumors and their matched synchronous
LM. We observed that PT did not cluster together with their matched
LM on transcriptome-wide gene expression level, indicating that the
biology of PT might differ from the biology of their matched
LM. When we looked at the concordance of different molecular sub-
types, we found that both the BRAF-like and the MSI-like signatures
were highly concordant between PT and matched LM. In contrast,
major discordances were observed for the CMS classification and the
TGFBa-like signature. Indeed, 41% of PT that were classified as CMS4
and 70% of PT that were classified as TGFBa-like lost their mesenchy-
mal profile in the matched LM. These differences were statistically
significant. Nevertheless, possibly due to the limited sample size, no
major differences were observed for the other CMS subgroups. Both
the TGFBa-like signature and CMS4 are characterized by high mesen-
chymal gene expression, which could be attributed to stromal cells as
well as to cancer cells.20,27-29 When we looked at the differences in
stroma percentage in our FFPE cohort, we did not observe a statisti-
cally significant difference in terms of stroma percentage in LM com-
pared to their matched PT. We found that stroma percentage was
statistically significantly associated with TGBa-like signature, but not
with the CMS classification. Nevertheless, this was not associated
with a change in the mesenchymal expression phenotype meaning
that the switch observed between PT and LM was not influenced by
the tumor stromal component. In addition, as also reported by
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Sandberg et al30 there was no linear association between stroma per-
centage and CMS classification. Because a quantification of the stro-
mal content represents a limited description of the tumor
microenvironment, we additionally applied transcriptomic signatures
to quantify the stromal contribution. The MCP-counter results
showed no systematic differences in microenvironment composition
between PT and LM, thus validating our findings of the visual stromal
quantification of the FFPE samples. Importantly, CMScaller, which
was designed to focus on expression of tumor cell-specific genes, also
indicated that subtype assignments of many matched PT and LM were
different as we have seen using the CMS classification. We are aware
that a dedicated translation of CMS classifiers to colorectal tumors
from different metastatic organs remains pending and that the
CMScaller, as highlighted by Eide et al,23 in its implementation is not
recommended for use with samples with a different human stromal
component than primary, like biopsies and metastatic tissue. Never-
theless, based on these results we can conclude that independent of
the classification used, most of the PT classified as mesenchymal by
gene expression lose this phenotype in their matched LM and this is
independent of the tissue in which the tumor arises and its intrinsic
microenvironment.
By looking at OS differences among molecular subgroups, we
could confirm that PT classified as CMS2 and TGFBi-like have sig-
nificantly longer mOS as compared to CMS4 and TGFBa-like PT
tumors, respectively. Surprisingly, this effect was lost when the
analyses were performed using LM as the basis for subgroup classi-
fication. Finally, no substantial differences were observed in terms
of mOS between PT that switched their transcriptomic profile in
the matched LM from epithelial to mesenchymal and from mesen-
chymal to epithelial, compared to tumors that did not change their
expression profile. We are aware that the survival analyses need to
be considered with caution because of the small sample size. No
conclusions could be derived for other molecular subgroups due to
low numbers of tumors classified as MSI-like and/or CMS1 and
BRAF m-like and/or CMS3. In addition, survival estimates were not
adjusted for relevant clinical variables, such as kind of treatment,
radical resection of liver metastasis and the presence of other met-
astatic lesions. Due to our inclusion criteria, patient selection did
not follow predefined criteria with respect to the treatment
received. Moreover, 90% of patients received liver resection while
10% of patients received liver biopsies, thus implying a potential
selection bias. Finally, with respect to the molecular classification,
grouping our patients by considering other clinical variables would
have led to even smaller subgroups and to inconclusive results.
Despite these limitations, our cohort represents a unique series of
synchronous mCRC where only LM were analyzed. By keeping in
mind the limitations above reported, our data suggest that the
transcriptomic profile of the PT is the driver of patient outcome
rather than the profile of their matched LM. This may indicate that
the PT has intrinsic properties that are constant despite changes
induced by a different microenvironment. Our data argue in favor
of using the PT rather than the distant metastases, for molecular
analyses of mCRC.
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